Rick Bright's whistleblower complaint argues that federal officials inappropriately tried to steer U.S. money to an unproven treatment for the pandemic coroanvirus By Jon Cohen, Charles PillerScience’s COVID-19 reporting is supported by the Pulitzer Center.Early last month, a top contracting officer at a U.S.
agency charged with accelerating the development of drugs to fight the COVID-19 pandemic got a request that made him feel uneasy.
Senior Trump administration officials had asked him to rapidly approve funding that would help a small pharmaceutical firm to further develop a still experimental drug being considered to treat COVID-19.